AU560829B2 - Continuous release pharmaceutical compositions - Google Patents

Continuous release pharmaceutical compositions

Info

Publication number
AU560829B2
AU560829B2 AU79986/82A AU7998682A AU560829B2 AU 560829 B2 AU560829 B2 AU 560829B2 AU 79986/82 A AU79986/82 A AU 79986/82A AU 7998682 A AU7998682 A AU 7998682A AU 560829 B2 AU560829 B2 AU 560829B2
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
release pharmaceutical
continuous release
polylactides
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU79986/82A
Other languages
English (en)
Other versions
AU7998682A (en
Inventor
Francis Gowland Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10519727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU560829(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of AU7998682A publication Critical patent/AU7998682A/en
Application granted granted Critical
Publication of AU560829B2 publication Critical patent/AU560829B2/en
Assigned to ZENECA LIMITED reassignment ZENECA LIMITED Alteration of Name(s) in Register under S187 Assignors: IMPERIAL CHEMICAL INDUSTRIES PLC
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Alteration of Name(s) in Register under S187 Assignors: ZENECA LIMITED
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU79986/82A 1981-02-16 1982-01-29 Continuous release pharmaceutical compositions Expired AU560829B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8104734 1981-02-16
GB8104734 1981-02-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU64988/86A Division AU582920B2 (en) 1981-02-16 1986-11-10 Continuous release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU7998682A AU7998682A (en) 1982-08-26
AU560829B2 true AU560829B2 (en) 1987-04-16

Family

ID=10519727

Family Applications (3)

Application Number Title Priority Date Filing Date
AU79986/82A Expired AU560829B2 (en) 1981-02-16 1982-01-29 Continuous release pharmaceutical compositions
AU64988/86A Expired AU582920B2 (en) 1981-02-16 1986-11-10 Continuous release pharmaceutical compositions
AU28407/89A Expired AU602623B2 (en) 1981-02-16 1989-01-11 Continuous release pharmaceutical compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU64988/86A Expired AU582920B2 (en) 1981-02-16 1986-11-10 Continuous release pharmaceutical compositions
AU28407/89A Expired AU602623B2 (en) 1981-02-16 1989-01-11 Continuous release pharmaceutical compositions

Country Status (20)

Country Link
US (2) US5004602A (cg-RX-API-DMAC7.html)
EP (1) EP0058481B2 (cg-RX-API-DMAC7.html)
JP (4) JPS57150609A (cg-RX-API-DMAC7.html)
AT (1) ATE22535T1 (cg-RX-API-DMAC7.html)
AU (3) AU560829B2 (cg-RX-API-DMAC7.html)
CA (1) CA1169090A (cg-RX-API-DMAC7.html)
DE (1) DE3273501D1 (cg-RX-API-DMAC7.html)
DK (1) DK164845B (cg-RX-API-DMAC7.html)
ES (1) ES8307845A1 (cg-RX-API-DMAC7.html)
FI (1) FI80594B (cg-RX-API-DMAC7.html)
GR (1) GR76791B (cg-RX-API-DMAC7.html)
HK (1) HK107890A (cg-RX-API-DMAC7.html)
HU (2) HU199695B (cg-RX-API-DMAC7.html)
IE (1) IE52535B1 (cg-RX-API-DMAC7.html)
MY (1) MY101545A (cg-RX-API-DMAC7.html)
NO (1) NO162103C (cg-RX-API-DMAC7.html)
NZ (1) NZ199732A (cg-RX-API-DMAC7.html)
PT (1) PT74434B (cg-RX-API-DMAC7.html)
YU (1) YU44066B (cg-RX-API-DMAC7.html)
ZA (1) ZA82565B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575066B2 (en) * 1983-08-26 1988-07-21 Novartis Ag Polyol ester

Families Citing this family (1049)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS6097918A (ja) * 1983-11-01 1985-05-31 Sumitomo Chem Co Ltd インタ−フエロン持続性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
CA1236641A (en) * 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
DE3434345A1 (de) * 1984-09-19 1986-03-27 Hoechst Ag, 6230 Frankfurt Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
NZ216122A (en) * 1985-05-10 1989-07-27 Univ Melbourne Stimulating ovulation in mares by administering gonadotrophin-releasing hormones
US5059422A (en) * 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5169633A (en) * 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4643191A (en) * 1985-11-29 1987-02-17 Ethicon, Inc. Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
EP0248531A3 (en) * 1986-05-02 1988-09-28 Southern Research Institute Encapsulated nucleic acids
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3701625A1 (de) * 1987-01-21 1988-08-04 Boehringer Ingelheim Kg Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
AU606383B2 (en) * 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
GB8716324D0 (en) * 1987-07-10 1987-08-19 Sandoz Ltd Organic compounds
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
US4866226A (en) * 1987-07-13 1989-09-12 Mitsubishi Denki Kabushiki Kaisha Multi-phase circuit breaker employing arc extinguishing apparatus
JPH0613602B2 (ja) * 1987-07-14 1994-02-23 三井東圧化学株式会社 ｄ▲ｌ▼−乳酸−グリコール酸共重合物の製造方法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
FR2634770B1 (fr) * 1988-07-29 1990-10-05 Rhone Poulenc Chimie Composition polyester erodable contenant de l'iode pour le traitement des eaux
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US5216050A (en) * 1988-08-08 1993-06-01 Biopak Technology, Ltd. Blends of polyactic acid
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5252642A (en) * 1989-03-01 1993-10-12 Biopak Technology, Ltd. Degradable impact modified polyactic acid
US5250584A (en) * 1988-08-31 1993-10-05 G-C Dental Industrial Corp. Periodontium-regenerative materials
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5247013A (en) * 1989-01-27 1993-09-21 Mitsui Toatsu Chemicals, Inc. Biocompatible polyester and production thereof
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE69022722T2 (de) * 1989-03-10 1996-05-02 Endorecherche Inc., Ste-Foy, Quebec Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
NZ234227A (en) * 1989-06-30 1991-08-27 Smithkline Beecham Corp Delayed release dosage form
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
GR1001164B (el) * 1989-07-07 1993-05-24 Endorecherche Inc Παραγωγα αρρενογονου ορμονης προς χρησιν εις την αναστολην δραστηριοτητος της στεροειδους ορμονης φυλου
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
WO1991000733A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Method of treatment of androgen-related diseases
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (cg-RX-API-DMAC7.html) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
DE59003337D1 (de) * 1989-10-16 1993-12-09 Danubia Petrochem Polymere Pressling mit retardierter Wirkstofffreisetzung.
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
DK0528978T3 (da) * 1990-05-16 2003-02-17 Southern Res Inst Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5620959A (en) * 1990-07-31 1997-04-15 Glaxo Wellcome Inc. Bombesin antagonists
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
NO302481B1 (no) * 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for et preparat med forlenget frigjöring, samt preparat med forlenget frigjöring
US5342557A (en) * 1990-11-27 1994-08-30 United States Surgical Corporation Process for preparing polymer particles
US7285531B1 (en) * 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
WO1995006415A1 (en) 1993-08-30 1995-03-09 Baylor College Of Medicine Senescent cell-derived inhibitors of dna synthesis
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
CA2129514A1 (en) * 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
WO1993023053A1 (en) * 1992-05-21 1993-11-25 Endorecherche Inc. INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5281419A (en) * 1992-09-28 1994-01-25 Thomas Jefferson University Biodegradable drug delivery system for the prevention and treatment of osteomyelitis
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
RU2185393C2 (ru) * 1993-01-06 2002-07-20 Кинертон Лимитед Сложный полиэфир и конъюгат на его основе
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5496923A (en) * 1993-09-20 1996-03-05 Mitsui Toatsu Chemicals, Inc. Purification process of aliphatic polyester
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
ES2255059T3 (es) 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
DE4406172C2 (de) * 1994-02-25 2003-10-02 Sanol Arznei Schwarz Gmbh Polyester
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6093697A (en) * 1994-11-07 2000-07-25 The University Of Virginia Patent Foundation Synthetic insulin mimetic substances
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
AU4611496A (en) * 1995-02-28 1996-09-18 Innapharma, Inc. Elcatonin controlled release microsphere formulation for treatment of osteoporosis
US6479457B2 (en) 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
KR100245395B1 (ko) 1995-06-09 2000-03-02 그린 마틴, 브라이언 쥐 테슬리 장기간의 국소 마취를 제공하는 제형 및 그 방법
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
DE69611513T2 (de) * 1995-08-29 2001-07-19 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur herstellung von polyhydroxycarbonsäure
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
EP0823448A4 (en) * 1996-02-23 1998-08-12 Kyowa Hakko Kogyo Kk PROCESS FOR THE PREPARATION OF POLYHYDROXYCARBOXYLIC ACID
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1997040085A2 (en) * 1996-04-23 1997-10-30 Kinerton Limited Acidic polylactic polymers
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
AU733867B2 (en) 1996-06-24 2001-05-31 Euro-Celtique S.A. Methods for providing safe local anesthesia
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5952455A (en) * 1996-10-11 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Process for producing polyhydroxycarboxylic acid
AU731553B2 (en) 1996-10-25 2001-04-05 Human Genome Sciences, Inc. Neutrokine alpha
ES2221019T3 (es) * 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US20020111603A1 (en) 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7235524B2 (en) * 1997-01-31 2007-06-26 Applied Research System Ars Holding N.V. Medicaments for initiating ovulation
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
ATE487737T1 (de) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
CA2297489A1 (en) * 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
ATE233097T1 (de) 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
WO1999038536A1 (en) * 1998-01-29 1999-08-05 Poly-Med Inc. Absorbable microparticles
JP2002501907A (ja) 1998-01-29 2002-01-22 キナートン・リミテッド 吸収可能なマイクロ粒子の製造法
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
PT2016951E (pt) 1998-03-17 2012-09-27 Genentech Inc Polipéptidos homólogos de vegf e de bmp1
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
AR020650A1 (es) * 1998-08-10 2002-05-22 Poly Med Inc Polimeros fosforilados y conjugados de los mismos
US20030007991A1 (en) * 1998-09-25 2003-01-09 Masters David B. Devices including protein matrix materials and methods of making and using thereof
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
EA006703B1 (ru) 1998-10-09 2006-02-24 Байоджен Айдек Эмэй Инк. СПОСОБ ЛЕЧЕНИЯ ИНДИВИДУУМА, СТРАДАЮЩЕГО ОТ ВЫЗВАННОГО ВИРУСОМ СИСТЕМНОГО ШОКА И/ИЛИ РАССТРОЙСТВА ДЫХАНИЯ, И СПОСОБ ИНДУЦИРОВАНИЯ ПРОТИВОВИРУСНОГО ОТВЕТА У ДАННОГО ИНДИВИДУУМА ПУТЕМ БЛОКАДЫ ПУТИ МЕТАБОЛИЗМА ЛИМФОТОКСИНА-β
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
EP1144013B1 (en) * 1998-11-02 2007-03-21 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Lactone bearing absorbable polymers
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
SI1149114T1 (sl) 1999-02-03 2014-08-29 Amgen Inc. Polipeptidi, vkljuäśeni v imunskem odgovoru
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
CA2363141C (en) 1999-02-26 2010-04-06 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
CA2377585A1 (en) 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US6682754B2 (en) * 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2266187T3 (es) * 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20030216480A1 (en) * 2000-05-24 2003-11-20 Holtzman Jordan Loyal Agents and method for increaseing brain chaperonin levels
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2077276A1 (en) 2000-06-23 2009-07-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
CN1269870C (zh) * 2000-08-07 2006-08-16 和光纯药工业株式会社 乳酸聚合物及其制备方法
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
CA2422095A1 (en) 2000-09-14 2002-03-21 Biogen, Inc. Tweak receptor agonists as anti-angiogenic agents
WO2002028366A2 (en) * 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US7776310B2 (en) 2000-11-16 2010-08-17 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
ES2536653T3 (es) 2000-11-28 2015-05-27 Amgen Inc. Polipéptidos implicados en la respuesta inmunitaria
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
AU2001298061A1 (en) 2000-12-13 2003-07-09 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
DE60226321T2 (de) 2001-06-01 2009-07-09 Wyeth Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP1408876A4 (en) 2001-06-22 2004-09-22 Durect Corp ZERO ORDER COAXIAL IMPLANTS WITH EXTENDED RELEASE
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
EP1572887A4 (en) 2001-08-24 2008-12-24 Neuren Pharmaceuticals Ltd NERVE REGENERATING PEPTIDE AND METHOD FOR THEIR USE IN THE TREATMENT OF A BRAIN DAMAGE
KR101008785B1 (ko) 2001-08-29 2011-01-14 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
AU2002325711C1 (en) * 2001-09-14 2008-05-29 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
ATE419863T1 (de) 2001-09-24 2009-01-15 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1439857B1 (en) 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
WO2003042344A2 (en) 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
BR0206469A (pt) * 2001-11-14 2004-01-13 Alza Corp Composição injetável para depósito
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003225895A1 (en) * 2002-03-19 2003-10-08 Purdue Research Foundation Microencapsulation using ultrasonic atomizers
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
JP4386741B2 (ja) 2002-04-15 2009-12-16 中外製薬株式会社 ｓｃＤｂライブラリーの作成方法
US7732149B2 (en) 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
WO2003092468A2 (en) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US8075585B2 (en) * 2002-08-29 2011-12-13 Stryker Corporation Device and method for treatment of a vascular defect
JP4317817B2 (ja) 2002-09-06 2009-08-19 アムジェン インコーポレイテッド 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP2959893A1 (en) * 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US7022481B2 (en) 2002-12-19 2006-04-04 Rosetta Inpharmatics Llc Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1440992A1 (fr) * 2003-01-21 2004-07-28 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Système catalytique de (co)polymérisation du lactide et du glycolide
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1594517T3 (da) 2003-01-28 2007-10-29 Microbia Inc Sammensætninger til behandlingen af gastrointestinale lidelser
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
AU2004277368B2 (en) 2003-03-07 2011-01-20 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
CN104001158A (zh) 2003-03-12 2014-08-27 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
US20060076295A1 (en) 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
CA2518667C (en) * 2003-03-14 2011-07-19 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
EP3000886A1 (en) 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
AU2004240630B2 (en) 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US7375076B2 (en) 2003-05-20 2008-05-20 The Regents Of The University Of Michigan Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
JP4808614B2 (ja) 2003-06-27 2011-11-02 アムジエン・フレモント・インコーポレイテツド 上皮成長因子受容体の欠失型変異体を認識する抗体、およびそれらの使用
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
CN103880955A (zh) 2003-07-18 2014-06-25 安姆根有限公司 肝细胞生长因子的特异性结合物
US8541051B2 (en) * 2003-08-14 2013-09-24 Halliburton Energy Services, Inc. On-the fly coating of acid-releasing degradable material onto a particulate
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
NZ545940A (en) 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
EP1675608B1 (en) 2003-09-12 2007-03-21 Wyeth Injectable calcium phosphate solid rods for delivery of osteogenic proteins
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US20050080313A1 (en) * 2003-10-10 2005-04-14 Stewart Daren L. Applicator for radiation treatment of a cavity
US7783006B2 (en) * 2003-10-10 2010-08-24 Xoft, Inc. Radiation treatment using x-ray source
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
ES2383525T3 (es) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
AU2004313245B2 (en) * 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
CN100534527C (zh) * 2003-12-30 2009-09-02 杜雷科特公司 用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
KR20070006708A (ko) * 2004-01-07 2007-01-11 트라이머리스 인코퍼레이티드 ＨＩＶ ｇｐ41 ＨＲ2-유래된 합성 펩티드 및 인간 면역결핍바이러스의 전염을 저해하는 치료에서 이들의 용도
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
US20070066525A1 (en) * 2004-02-04 2007-03-22 Lee John C Compositions and therapeutic methods using morphogenic proteins
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
EP1726647B1 (en) 2004-03-19 2015-01-07 GenomIdea, Inc. Gene promoting vascular endothelial cell growth
AU2005227313A1 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
DK2447252T3 (da) 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer
EP1763362B1 (en) 2004-05-25 2011-07-06 Stryker Corporation Use of op-1 for treating cartilage defects
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
JP4852539B2 (ja) 2004-06-22 2012-01-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
US20080280973A1 (en) * 2004-06-28 2008-11-13 Wender Paul A Laulimalide Analogues as Therapeutic Agents
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US8541028B2 (en) * 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
PT1786400E (pt) 2004-08-12 2009-06-19 Quest Pharmaceutical Services Composições farmacêuticas para a libertação controlada de compostos biologicamente activos
WO2006023603A2 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
EP1802326A2 (en) * 2004-09-09 2007-07-04 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins
EA014852B1 (ru) * 2004-09-17 2011-02-28 Дьюрект Корпорейшн Система контролируемой доставки
CN101072580B (zh) 2004-10-06 2012-08-22 农业生物技术有限公司 抗体制备方法
FR2876379B1 (fr) * 2004-10-08 2008-09-05 Isochem Sa Procede de polymerisation des o-carboxy anhydrides
WO2006041048A1 (ja) 2004-10-15 2006-04-20 Mie University 肝再生・修復制御剤
AU2005307831A1 (en) 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
CN101128483B (zh) 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
JP5425398B2 (ja) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
SG160437A1 (en) 2004-12-22 2010-04-29 Ambrx Inc Modified human growth hormone
CA2590239A1 (en) * 2004-12-23 2006-07-06 Durect Corporation Controlled release compositions
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
RU2007140348A (ru) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) Способы и композиции для лечения заболеваний цнс
TW200714313A (en) 2005-04-08 2007-04-16 Chugai Pharmaceutical Co Ltd Antibodies that substitute for coagulation factor VIII
EP1871796A4 (en) * 2005-04-20 2009-01-14 Auckland Uniservices Ltd VESICULINE
WO2006116565A2 (en) * 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
ATE382337T1 (de) 2005-04-28 2008-01-15 Nipro Corp Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
US7417072B2 (en) 2005-05-12 2008-08-26 Wisconsin Alumni Research Foundation Blockade of Pin1 prevents cytokine production by activated immune cells
JP5794721B2 (ja) 2005-05-17 2015-10-14 サーコード バイオサイエンス インコーポレイテッド 眼障害の治療のための組成物および方法
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
TW200718780A (en) 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
PL2163562T3 (pl) 2005-06-21 2014-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
EP2388276A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP2374451A3 (en) 2005-07-27 2012-01-25 University of Florida Research Foundation, Inc. Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
BRPI0615573A2 (pt) 2005-09-08 2011-05-24 Tufts College análogos de glp-1 estabilizados
KR20080074108A (ko) * 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
CA2625447C (en) 2005-09-29 2015-06-09 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compositions and methods for stimulating gastrointestinal motility
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
CN101330929B (zh) 2005-10-14 2014-03-05 学校法人福冈大学 胰岛移植中的移植胰岛障碍抑制剂
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
ES2547554T3 (es) 2005-11-16 2015-10-07 Ambrx, Inc. Métodos y composiciones que comprenden aminoácidos no naturales
US20090269335A1 (en) 2005-11-25 2009-10-29 Keio University Therapeutic agent for prostate cancer
CA2632797A1 (en) 2005-12-01 2007-06-07 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases using toll like receptor agonists
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
AU2006320479B2 (en) 2005-12-02 2012-11-08 Biogen Ma Inc. Treatment of conditions involving demyelination
WO2007066313A2 (en) 2005-12-05 2007-06-14 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for modulating an immune response
WO2008024128A2 (en) 2005-12-05 2008-02-28 Simon Delagrave Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
WO2007070432A2 (en) 2005-12-13 2007-06-21 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
AU2006324477A1 (en) 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
KR20080094910A (ko) 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 신규 단백질 발현계
JP5242415B2 (ja) * 2006-01-18 2013-07-24 フォアシーエイサー ファーマシューティカルズ インコーポレイテッド 高い安定性を持つ薬理組成物
CN104189907A (zh) 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
CU23388B6 (es) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
AR059300A1 (es) * 2006-02-02 2008-03-26 Trimeris Inc Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
AU2007229301B2 (en) * 2006-03-17 2013-08-01 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20090298761A1 (en) 2006-05-17 2009-12-03 Donald Engelman Methods of treating cartilage defects using a soluble morphogenic protein complex
EP2548578B1 (en) 2006-05-17 2014-08-20 The Ludwig Institute for Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
BRPI0711896A2 (pt) 2006-05-22 2012-07-17 Univ Columbia sistemas e métodos de troca sem membrana microfluida usando filtração da extração de correntes de saìda de fluido.
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
EP2049570B1 (en) 2006-06-01 2016-08-10 President and Fellows of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
EP2047863B1 (en) 2006-06-08 2013-07-31 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
CN101517075A (zh) 2006-07-13 2009-08-26 中外制药株式会社 细胞死亡诱导剂
WO2008008827A2 (en) * 2006-07-13 2008-01-17 Medtronic, Inc. Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
EP2574625B1 (en) 2006-07-21 2015-02-25 HuBit genomix, Inc. Remedy for renal disease
US7666423B2 (en) 2006-07-28 2010-02-23 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
JP5840345B2 (ja) 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
CN101529255A (zh) 2006-11-14 2009-09-09 健泰科生物技术公司 神经元再生的调控剂
KR101503937B1 (ko) 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AR064381A1 (es) * 2006-12-18 2009-04-01 Takeda Pharmaceutical Composicion de liberacion sostenida y metodos para producirla
CN103405768A (zh) 2006-12-20 2013-11-27 爱克索马技术有限公司 用于治疗IL-1β相关疾病的方法
CN103360495B (zh) 2007-01-09 2016-06-08 比奥根Ma公司 Sp35抗体及其用途
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
GEP20135853B (en) 2007-02-02 2013-06-25 Univ Pierre And Marie Curie Method of myelination and oligodendrocyte differentiation promotion
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
WO2013106175A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
JP2010523564A (ja) * 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド 抗ウイルス性ペプチド治療薬の送達のための新規製剤
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
MX2009010907A (es) * 2007-04-13 2010-03-17 Univ North Texas Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer.
EP2153736B1 (en) 2007-05-11 2017-04-19 Bizen Chemical Co., Ltd. Novel leukotriene receptor antagonist from marine sources
WO2008143992A2 (en) 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0710976D0 (en) 2007-06-07 2007-07-18 Bioalvo Am Screening method
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
AU2008268461B2 (en) 2007-06-22 2015-04-09 Children's Medical Center Corporation Methods and uses thereof of prosaposin
MX2009013765A (es) 2007-06-27 2010-02-01 Auckland Uniservices Ltd Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.
US20100129355A1 (en) 2007-07-26 2010-05-27 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
DE102007036101A1 (de) 2007-08-01 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue glycolidreiche Copolymere
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
SG10201500328QA (en) 2007-08-21 2015-03-30 Amgen Inc Human c-fms antigen binding proteins
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
CN101998855A (zh) * 2007-10-02 2011-03-30 戴维·布兰斯基 用于增强婴儿生长和发育的内源性大麻素
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
US20090123508A1 (en) * 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
EP2219620B1 (en) * 2007-11-13 2017-07-19 Surmodics, Inc. Viscous terpolymers as drug delivery platform
MY158903A (en) 2007-11-16 2016-11-30 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
BRPI0821145B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
KR101643005B1 (ko) 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
DK2391650T3 (en) 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
WO2009100154A1 (en) * 2008-02-04 2009-08-13 Trustees Of Columbia University In The City Of New York Fluid separation devices, systems and methods
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
PT2251006T (pt) * 2008-02-22 2017-10-13 Toray Industries Micropartículas e suas composições farmacêuticas
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
NZ588442A (en) 2008-06-09 2013-01-25 Univ Muenchen L Maximilians Pyrazole, isoxazole and imidazole derivatives for treating diseases linked to protein aggregation and neurodegenerative diseases
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
CN102256609B (zh) 2008-07-30 2014-02-19 米辛瑟斯有限公司 衍生自前胃胞外基质的组织支架
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
WO2010030813A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Methods for inhibiting ocular angiogenesis
MX2011002837A (es) 2008-09-19 2011-07-29 Medimmune Llc Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos.
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
CN102224238B (zh) 2008-09-26 2015-06-10 Ambrx公司 非天然氨基酸复制依赖性微生物和疫苗
JP2012504969A (ja) 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
CN102307593B (zh) 2008-10-22 2016-04-13 弗·哈夫曼-拉罗切有限公司 轴突变性的调节
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA2744120A1 (en) 2008-11-17 2010-05-20 The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, A vaccinia virus protein a46 peptide and use thereof
MY159483A (en) 2008-11-26 2017-01-13 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
WO2010070136A2 (en) 2008-12-19 2010-06-24 Centre de Recherche Public de la Santé Novel caviidae allergens and uses thereof
US20110312872A1 (en) 2008-12-22 2011-12-22 Universität Regensburg Norrin in the treatment of diseases associated with an increased tgf-beta activity
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
KR101040396B1 (ko) 2009-01-20 2011-06-09 한올바이오파마주식회사 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
CA2750003A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
WO2010085608A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
MX2011008542A (es) 2009-02-13 2011-09-01 Novartis Ag Molecula de acido nucleico de un racimo biosintetico que codifica sintasas peptidicas no ribosomales y usos de la misma.
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
EP2398467A1 (en) 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Particles comprising drospirenone encapsulated in a polymer
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
HUE065036T2 (hu) 2009-05-05 2024-04-28 Amgen Inc FGF21 mutánsok és alkalmazásaik
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
IN2012DN00352A (cg-RX-API-DMAC7.html) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
MX2011013903A (es) 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
WO2011010131A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Compositions comprising an oxoisoquinoline methylbenzamide and a polymer
WO2011010132A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
US20120183539A1 (en) 2009-07-31 2012-07-19 Shin Maeda Cancer Metastasis Inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2305810A1 (en) 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP2488186B1 (en) 2009-10-16 2017-05-24 National University of Singapore Anti-neoplastic uses of artemin antagonists
JP5746191B2 (ja) 2009-10-19 2015-07-08 ハナル バイオファーマ カンパニーリミテッドＨａｎＡｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 修飾されたヒト腫瘍壊死因子受容体−１ポリペプチドまたはその断片及びその製造方法
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2490698A4 (en) 2009-10-22 2013-09-25 Hoffmann La Roche MODULATION OF AXONES DEGENERATION
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
DK3202898T3 (en) 2009-11-02 2019-01-14 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
CA2780761A1 (en) 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
AU2010339794B2 (en) 2009-12-17 2016-09-22 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
EP2525792A1 (en) 2010-01-19 2012-11-28 Medizinische Universität Wien Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
JP6046493B2 (ja) 2010-01-27 2016-12-14 チルドレンズ メディカル センター コーポレーション プロミニン−１の血管新生促進フラグメントおよびその使用
EP2528943A1 (en) 2010-01-28 2012-12-05 Novo Nordisk Health Care AG Factor vii fusion polypeptides
WO2011099007A1 (en) 2010-02-10 2011-08-18 Nayacure Therapeutics Ltd. Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
EP2554552B1 (en) 2010-03-26 2015-05-13 The University of Tokushima Novel anti-cd98 antibody and use thereof
EP3670534A3 (en) 2010-04-15 2020-09-09 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
WO2011131626A1 (en) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
JP5894574B2 (ja) 2010-04-22 2016-03-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
WO2011138457A1 (en) 2010-05-07 2011-11-10 Technische Universität Graz Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
JP6033218B2 (ja) 2010-05-21 2016-11-30 ペプティメド， インコーポレイテッド がんを治療するための試薬および方法
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
KR101731008B1 (ko) 2010-06-16 2017-04-27 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
WO2011157819A2 (en) 2010-06-18 2011-12-22 Xiberscience Gmbh Peptides as active agents to stabilize biological barriers
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US9211175B2 (en) 2010-07-08 2015-12-15 Covidien Lp Self-detachable medical devices
EP2593476A2 (en) 2010-07-16 2013-05-22 Ablynx N.V. Modified single domain antigen binding molecules and uses thereof
FR2962646B1 (fr) 2010-07-16 2012-06-22 Sofradim Production Prothese avec element radio-opaque
UY33517A (es) 2010-07-19 2012-02-29 Astrazeneca Ab Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CA2809825A1 (en) * 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Biodegradable terpolymers and terpolymer blends as pressure-sensitive adhesives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US8865170B2 (en) 2010-09-28 2014-10-21 Sekisui Chemical Co., Ltd. Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
US9572907B2 (en) 2010-10-01 2017-02-21 Covidien Lp Implantable polymeric films
EP2621516B1 (en) 2010-10-01 2016-06-22 Biogen MA Inc. Interferon-beta for use as monotherapy or in combination with other cancer therapies
US9861590B2 (en) 2010-10-19 2018-01-09 Covidien Lp Self-supporting films for delivery of therapeutic agents
US8920867B2 (en) 2010-10-19 2014-12-30 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US8632839B2 (en) 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
MX2013004679A (es) 2010-10-25 2014-02-20 Univ Minnesota Composicion terapeutica para el tratamiento de glioblastoma.
CA2815181C (en) 2010-10-27 2020-09-15 William Gleason Richards Dkk1 antibodies and methods of use
US8680045B2 (en) 2010-11-01 2014-03-25 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
GB201019467D0 (en) 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
KR20180069083A (ko) 2010-11-24 2018-06-22 렉시컨 파마슈티컬스 인코퍼레이티드 노텀 펙틴아세틸에스터라제에 대한 항체
ES2693232T3 (es) 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Agente terapéutico que induce citotoxicidad
US8754037B2 (en) 2010-12-23 2014-06-17 Hanall Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US9144634B2 (en) 2011-01-14 2015-09-29 Covidien Lp Medical device with intrapore films
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
PL2667715T3 (pl) 2011-01-27 2018-02-28 Neuren Pharmaceuticals Limited Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
WO2012122515A1 (en) 2011-03-10 2012-09-13 Genentech, Inc. Treatment of disorders with altered vascular barrier function
US10059746B2 (en) 2011-04-04 2018-08-28 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
CA2832663C (en) 2011-04-25 2016-02-09 Shandong Luye Pharmaceutical Co., Ltd. Risperidone sustained release microsphere composition
AU2012249360B2 (en) 2011-04-29 2015-12-24 University Of Washington Therapeutic nuclease compositions and methods
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
DK2705013T3 (en) 2011-05-04 2016-07-18 Balance Therapeutics Inc Pentylenetetrazolderivater
EP2707718A1 (en) 2011-05-10 2014-03-19 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CA2835628C (en) 2011-05-11 2023-01-03 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EA032666B1 (ru) 2011-06-14 2019-06-28 Бикам Фармасьютикалз, Инк. Опсинсвязывающие лиганды и способы их применения
CA2838340A1 (en) 2011-06-17 2012-12-20 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
FR2977790B1 (fr) 2011-07-13 2013-07-19 Sofradim Production Prothese pour hernie ombilicale
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US8579924B2 (en) 2011-07-26 2013-11-12 Covidien Lp Implantable devices including a mesh and a pivotable film
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
US9605083B2 (en) 2011-08-16 2017-03-28 Emory University JAML specific binding agents, antibodies, and uses related thereto
EP2745113B1 (en) 2011-08-16 2017-03-22 Evotec (München) GmbH Markers for susceptibility to an inhibitor of an src-family kinase
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US9701731B2 (en) 2011-08-19 2017-07-11 Children's Medical Center Corporation VEGF-binding protein for blockade of angiogenesis
US9782957B2 (en) 2011-08-24 2017-10-10 Covidien Lp Medical device films
JP2014526441A (ja) 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
JO3625B1 (ar) 2011-09-22 2020-08-27 Amgen Inc بروتينات رابطة للأنتيجين cd27l
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
JP6352634B2 (ja) 2011-09-30 2018-07-04 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US8906860B2 (en) 2011-10-14 2014-12-09 The Board Of Trustees Of The University Of Illinois Methods and compositions inhibiting tumor cell proliferation
US20130172265A1 (en) 2011-10-14 2013-07-04 The Board Of Trustees Of The University Of Illinois Methods and Compositions for Inhibiting Tumor Cell Proliferation
EP2768307B1 (en) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9179994B2 (en) 2011-10-25 2015-11-10 Covidien Lp Implantable film/mesh composite
US8932621B2 (en) 2011-10-25 2015-01-13 Covidien Lp Implantable film/mesh composite
US9005308B2 (en) 2011-10-25 2015-04-14 Covidien Lp Implantable film/mesh composite for passage of tissue therebetween
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013075048A1 (en) 2011-11-16 2013-05-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
EP3750544B1 (en) 2011-11-30 2025-03-05 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
BR112014012997A2 (pt) 2011-11-30 2017-06-13 Bikam Pharmaceuticals Inc ligantes que se ligam à opsina, composições e métodos de uso
BR112014013106A2 (pt) 2011-12-01 2017-06-13 Bikam Pharmaceuticals Inc ligantes de ligação à opsina, composições e métodos de uso
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
US10736935B2 (en) 2011-12-22 2020-08-11 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP2802602B1 (en) 2012-01-11 2019-03-27 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2626066A1 (en) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
WO2013148165A1 (en) 2012-03-29 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Click nucleic acids
US10206769B2 (en) 2012-03-30 2019-02-19 Covidien Lp Implantable devices including a film providing folding characteristics
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
US20150118237A1 (en) 2012-04-23 2015-04-30 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
FR2992662B1 (fr) 2012-06-28 2014-08-08 Sofradim Production Tricot avec picots
FR2992547B1 (fr) 2012-06-29 2015-04-24 Sofradim Production Prothese pour hernie
EP2866821B1 (en) 2012-07-02 2018-11-14 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
EP2695950A1 (en) 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
JP2015526471A (ja) 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
HUE042262T2 (hu) 2012-10-17 2019-06-28 Vascular Biogenics Ltd FAS-kimérát kifejezõ adenovírus és alkalmazása rákkezelési módszerekben
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2014073292A1 (ja) 2012-11-09 2014-05-15 ジーンフロンティア株式会社 癌治療のための抗adam28抗体
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP6326066B2 (ja) 2012-12-20 2018-05-16 メディミューン，エルエルシー 凝集プロファイルが改善されている液状抗体製剤
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
ES2753950T3 (es) 2013-03-15 2020-04-15 Amgen Res Munich Gmbh Moléculas de unión monocatenarias que comprenden ABP del extremo N
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
MX378292B (es) 2013-03-15 2025-03-10 Amgen Inc Anticuerpos humanos pac1.
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2014151962A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
EP2970483A2 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
EP2987484B1 (en) * 2013-04-18 2018-12-19 Shandong Luye Pharmaceutical Co., Ltd. Goserelin sustained release microsphere pharmaceutical composition
EP2999797B1 (en) 2013-05-21 2018-07-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
US20160130585A1 (en) 2013-05-28 2016-05-12 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
EP2810648A1 (en) 2013-06-04 2014-12-10 Daniel Rauh Targeting domain-domain interaction for the identification of kinase modulators
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
US20160129089A1 (en) 2013-06-13 2016-05-12 Antisense Therapeutics Ltd Combination therapy
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP2835135A3 (en) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Means and methods for treating pseudomonas infection
AU2013396206B2 (en) 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
EA037355B1 (ru) 2013-07-31 2021-03-17 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf-15)
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
AU2014318748B2 (en) 2013-09-11 2019-02-28 Duquesne University Of The Holy Ghost Novel anthranilic amides and the use thereof
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
EP2808338B1 (en) 2013-09-16 2016-03-30 CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Mutant calreticulin for the diagnosis of myeloid malignancies
EP3047857A4 (en) 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
GB201316738D0 (en) 2013-09-20 2013-11-06 Rainbow Medical Engineering Ltd Implantable Medical Devices
ES2724300T3 (es) 2013-09-25 2019-09-10 Univ Cornell Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
JP6637415B2 (ja) 2013-10-15 2020-01-29 ザ スクリプス リサーチ インスティテュート キメラ抗原受容体ｔ細胞スイッチおよびその使用
WO2015056808A1 (en) 2013-10-15 2015-04-23 Genefrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
WO2015061856A1 (en) 2013-10-30 2015-05-07 University Of Western Australia Neuroprotective peptides
WO2015066550A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
DK3076967T3 (da) 2013-12-03 2021-10-25 Intra Cellular Therapies Inc Fremgangsmåder til behandling af residuelle symptomer på skizofreni
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
WO2015121457A1 (en) 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
CA2939626C (en) 2014-02-20 2023-01-17 Allergan, Inc. Complement component c5 antibodies
RU2018135371A (ru) 2014-02-27 2018-12-10 Аллерган, Инк. АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
AU2015226881A1 (en) 2014-03-07 2016-09-29 Intonation Research Laboratories Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)
US10472334B2 (en) 2014-03-14 2019-11-12 The University Of North Carolina At Chapel Hill Small molecules for inhibiting male fertility
AU2015240884B2 (en) 2014-03-31 2020-06-18 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
MX2016013046A (es) 2014-04-04 2017-02-15 Intra Cellular Therapies Inc Compuestos organicos.
CN106535898A (zh) 2014-04-04 2017-03-22 细胞内治疗公司 有机化合物
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
WO2015173398A1 (en) 2014-05-15 2015-11-19 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of slc38a9 and their use in therapy
WO2015179415A1 (en) 2014-05-19 2015-11-26 Novartis Ag Methods of treating anorexia
US11357748B2 (en) 2014-05-30 2022-06-14 The Johns Hopkins University Methods for treating mendelian disorders of the epigenetic machinery
MX355107B (es) 2014-06-03 2018-04-04 Xbiotech Inc Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus.
AU2015275128C1 (en) 2014-06-09 2020-02-13 Kyowa Kirin Co., Ltd. The effective and efficient control of serum phosphate for optimal bone formation
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
CA2952231A1 (en) 2014-06-13 2015-12-17 Santa Maria Biotherapeutics, Inc. Formulated receptor polypeptides and related methods
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
US11661462B2 (en) 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
CA3133162C (en) 2014-08-12 2024-02-13 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CA2958879A1 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
AU2015307186A1 (en) 2014-08-27 2017-04-13 Peptimed, Inc. Anti-tumor compositions and methods
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MX386613B (es) 2014-10-21 2025-03-19 Sciclone Pharmaceuticals Int Sg Pte Ltd El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
CN114853868A (zh) 2014-10-24 2022-08-05 百时美施贵宝公司 修饰的fgf-21多肽及其用途
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
WO2016079321A1 (en) 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
WO2016123142A1 (en) 2015-01-26 2016-08-04 The University Of Chicago IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
RU2722832C2 (ru) 2015-02-23 2020-06-04 Сигалл Терапьютикс Сас Неприродные семафорины класса 3 и их медицинское применение
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US10851144B2 (en) 2015-04-10 2020-12-01 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP4276116A3 (en) 2015-04-17 2024-01-17 Amgen Research (Munich) GmbH Bispecific antibody constructs for cdh3 and cd3
WO2016186977A1 (en) 2015-05-15 2016-11-24 The Johns Hopkins University Novel fluoride prenatal dietary supplement
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
WO2017007955A1 (en) 2015-07-07 2017-01-12 The Research Foundation For The State University Of New York Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
ES2546566B2 (es) * 2015-07-23 2016-09-14 Universidade De Santiago De Compostela Sistema para la administración de sustancias biológicamente activas preparado por técnicas de espumado empleando gases comprimidos o fluidos supercríticos
EP3328376A4 (en) 2015-07-31 2019-03-13 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
JP6863981B2 (ja) 2015-07-31 2021-04-21 ザ・ジョンズ・ホプキンス・ユニバーシティー グルタミン類似体のプロドラッグ
EP3328374A4 (en) 2015-07-31 2019-03-13 The Johns Hopkins University GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
MX2018005232A (es) 2015-11-03 2018-08-15 Ambrx Inc Anticuerpos anti-cd3 novedosos y sus usos.
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
EP3370763B1 (en) 2015-11-03 2024-04-10 Regents of the University of Minnesota Cd200 inhibitors and methods of use thereof
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
JP6954842B2 (ja) 2015-12-25 2021-10-27 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
TWI748984B (zh) 2016-02-03 2021-12-11 德商安美基研究（慕尼黑）公司 Bcma及cd3雙特異性t細胞嚙合抗體構築體
US10098909B2 (en) 2016-02-05 2018-10-16 University Of South Florida Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
CA3013904C (en) 2016-02-10 2023-12-12 Rutgers, The State University Of New Jersey Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
EP3808764A1 (en) 2016-05-04 2021-04-21 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US20190241878A1 (en) 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
AU2017292791B2 (en) 2016-07-06 2023-05-25 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
CN110214021A (zh) 2016-08-08 2019-09-06 安进公司 使用抗硬化蛋白抗体改善结缔组织附着的方法
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
MY209831A (en) 2016-09-06 2025-08-07 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
JP7048572B6 (ja) 2016-09-16 2023-12-20 リサーチ トライアングル インスティテュート テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CA3040343A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018107697A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肺纤维化的方法
US20190365871A1 (en) 2016-12-15 2019-12-05 Talengen International Limited Drug for preventing and treating osteoporosis and uses thereof
WO2018107690A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
CA3047175A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for mitigating heart disease
US11311607B2 (en) 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
JP7182793B2 (ja) 2016-12-15 2022-12-05 タレンゲン インターナショナル リミテッド 病理学的腎組織損傷を予防及び治療するための方法
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
CN110494445B (zh) 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
EP3567054A4 (en) 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
US11529391B2 (en) 2017-01-09 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
JP2020505438A (ja) 2017-01-10 2020-02-20 ノダス・セラピューティクスＮｏｄｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ インテグリン結合性ポリペプチド−Ｆｃ融合タンパク質および免疫調節物質を用いる併用がん治療法
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US20190328792A1 (en) 2017-01-11 2019-10-31 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
US10421968B2 (en) 2017-03-15 2019-09-24 Versitech Limited Amphiphilic dendrimers complexed with siRNA for treatment of cancer
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
CN110691973B (zh) 2017-04-25 2024-11-29 普罗瑟拉生物公司 用于定量间α抑制剂蛋白的方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
EP3619227A1 (en) 2017-05-04 2020-03-11 Helsingin Yliopisto C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
JP7325936B2 (ja) 2017-05-05 2023-08-15 アムジエン・インコーポレーテツド 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
US11180518B2 (en) 2017-05-12 2021-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
JP7335609B2 (ja) 2017-06-19 2023-08-30 タレンゲン インターナショナル リミテッド Ｇｌｐ－１／ｇｌｐ－１ｒを調節制御する方法および薬剤
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
KR20200019122A (ko) 2017-06-20 2020-02-21 암젠 인크 Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
CA3066251A1 (en) 2017-06-21 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
PE20200757A1 (es) 2017-07-11 2020-07-27 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos
JP2020528054A (ja) 2017-07-19 2020-09-17 オークランド ユニサービシズ リミテッド サイトカインモジュレーション
EP3658145A4 (en) 2017-07-26 2021-04-21 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
KR102667268B1 (ko) 2017-07-26 2024-05-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
EA202090581A1 (ru) 2017-10-04 2020-08-31 Амген Инк. Продукты слияния транстиретина и иммуноглобулина
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019089365A1 (en) 2017-10-30 2019-05-09 Enterin Laboratories, Inc. New squalamine solid forms and methods of making the same
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111315780A (zh) 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
WO2019117685A2 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 항-igf1r 항체 및 그 용도
JP7214245B2 (ja) 2017-12-15 2023-01-30 タレンゲン インターナショナル リミテッド 骨関節炎を予防または治療するための方法および薬剤
JP2021506851A (ja) 2017-12-19 2021-02-22 マサチューセッツ インスティテュート オブ テクノロジー 抗原−アジュバントカップリング試薬および使用の方法
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EP3747469A4 (en) 2018-01-31 2022-03-23 Motokazu Kato THERAPEUTIC FOR ASTHMA WITH IL-6 INHIBITOR
CA3090062A1 (en) 2018-02-09 2019-08-15 Nestle Skin Health Sa Treatment of atopic dermatitis with moderate to severe excoriation
EP3765524A4 (en) 2018-03-14 2021-12-22 Surface Oncology, Inc. ANTIBODIES THAT BIND TO CD39 AND THEIR USES
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
AU2019239324A1 (en) 2018-03-22 2020-10-01 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
JP2021519271A (ja) 2018-03-23 2021-08-10 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
MX2020010301A (es) 2018-03-29 2020-10-20 Helsingin Yliopisto Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.
EP3774879A1 (en) 2018-03-30 2021-02-17 Amgen Inc. C-terminal antibody variants
WO2019199685A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
EP3781689A1 (en) 2018-04-19 2021-02-24 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
ES3028377T3 (en) 2018-06-08 2025-06-19 Intra Cellular Therapies Inc Fused gamma-carbolines for acute treatment of anxiety or depression
KR20250034203A (ko) 2018-06-11 2025-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
AU2019284362A1 (en) 2018-06-11 2021-01-07 University Of Florida Research Foundation, Inc. Materials and methods for treating stress-related disorders and cancer
EP3807644A4 (en) 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
CN111417655A (zh) 2018-08-28 2020-07-14 润俊(中国)有限公司 抗cd3抗体叶酸生物偶联物及其用途
JP2022500362A (ja) 2018-08-29 2022-01-04 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
AU2019331490B2 (en) 2018-08-31 2025-04-24 Intra-Cellular Therapies, Inc. Novel methods
CA3108553A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
SMT202400087T1 (it) 2018-09-11 2024-03-13 Ambrx Inc Coniugati polipeptidici di interleuchina-2 e loro usi
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
CN112771071A (zh) 2018-09-28 2021-05-07 麻省理工学院 胶原蛋白定位的免疫调节分子及其方法
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
AU2019399474A1 (en) 2018-12-13 2021-06-03 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
BR112021011792A2 (pt) 2018-12-17 2021-08-31 Intra-Cellular Therapies, Inc. Composto orgânico
CN113597319A (zh) 2019-01-04 2021-11-02 分解治疗有限责任公司 用核酸酶融合蛋白治疗干燥症
US11680105B2 (en) 2019-01-17 2023-06-20 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
EP3941511A2 (en) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
WO2020198136A1 (en) 2019-03-22 2020-10-01 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
EP3949989A4 (en) 2019-03-29 2022-12-14 Chugai Seiyaku Kabushiki Kaisha Anti il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
CA3135694A1 (en) 2019-04-17 2020-10-22 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US20220218799A1 (en) 2019-05-10 2022-07-14 Talengen International Limited Method and medicine for treating amyotrophic lateral sclerosis
CN113924119A (zh) 2019-05-31 2022-01-11 国立大学法人大阪大学 新型的消化器官癌治疗剂及其筛选方法
TW202112808A (zh) 2019-06-05 2021-04-01 日商中外製藥股份有限公司 抗體切斷部位結合分子
WO2020250915A1 (ja) 2019-06-10 2020-12-17 中外製薬株式会社 サイトカイン阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
EP3997112A1 (en) 2019-07-08 2022-05-18 Amgen, Inc Multispecific transthyretin immunoglobulin fusions
US20230057904A1 (en) 2019-07-10 2023-02-23 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
US20220281966A1 (en) 2019-07-26 2022-09-08 Amgen Inc. Anti-il13 antigen binding proteins
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
CN114555634B (zh) 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
TW202521984A (zh) 2019-09-25 2025-06-01 美商表面腫瘤學有限責任公司 抗ｉｌ－２７抗體及其用途
TWI745114B (zh) 2019-10-11 2021-11-01 日商中外製藥股份有限公司 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
JP7707161B2 (ja) 2019-10-23 2025-07-14 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
EP4058485A1 (en) 2019-11-13 2022-09-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
US20230067910A1 (en) 2019-11-19 2023-03-02 Modag Gmbh Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides
KR20250095745A (ko) 2020-01-06 2025-06-26 백시넥스 인코포레이티드 항-ccr8 항체 및 이의 용도
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
US20230066726A1 (en) 2020-01-17 2023-03-02 Talengen International Limited Method for treatment of nerve injury and related disease
CA3167202A1 (en) 2020-02-06 2021-08-12 Jinan Li Method and drug for preventing and treating multiple sclerosis
CN115605219A (zh) 2020-02-11 2023-01-13 泰伦基国际有限公司（Hk） 一种治疗病毒性肺炎的方法和药物
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
CA3169325A1 (en) 2020-02-26 2021-09-02 Jinan Li Method and drug for preventing and treating abnormal blood pressure condition
WO2021173929A1 (en) 2020-02-26 2021-09-02 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
EP4121459A1 (en) 2020-03-19 2023-01-25 Amgen Inc. Antibodies against mucin 17 and uses thereof
KR20220158036A (ko) 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
CA3176937A1 (en) 2020-03-24 2021-09-30 Talengen International Limited Method and drug for promoting degradation of misfolded protein and aggregate thereof
WO2021190563A1 (zh) 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗亨廷顿病的方法和药物
JP7576861B2 (ja) 2020-03-24 2024-11-01 タレンゲン インターナショナル リミテッド アルツハイマー病を治療する方法及び薬剤
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
JP7624240B2 (ja) 2020-05-11 2025-01-30 タレンゲン インターナショナル リミテッド 脊髄性筋萎縮症を治療する方法及び薬剤
WO2021248081A1 (en) 2020-06-05 2021-12-09 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Acvr1 (alk2) receptor inhibition to treat neurological diseases
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
MX2022015764A (es) 2020-06-19 2023-01-19 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis.
EP4171614A1 (en) 2020-06-29 2023-05-03 Resolve Therapeutics, LLC Treatment of sjogren's syndrome with nuclease fusion proteins
CA3190649A1 (en) 2020-07-31 2022-02-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising cell expressing chimeric receptor
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
EP4203999A1 (en) 2020-08-26 2023-07-05 Scancell Limited Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
KR20230107635A (ko) 2020-11-17 2023-07-17 탈렌젠 인터내셔널 리미티드 Bdnf 수준의 향상을 위한 방법 및 약물
WO2022105789A1 (zh) 2020-11-17 2022-05-27 泰伦基国际有限公司 一种提高ngf水平的方法和药物
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
EP4294834A2 (en) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Single domain antibodies that neutralize sars-cov-2
WO2022191306A1 (ja) 2021-03-12 2022-09-15 中外製薬株式会社 重症筋無力症の治療または予防用の医薬組成物
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
JP2024516970A (ja) 2021-05-07 2024-04-18 サーフィス オンコロジー， エルエルシー 抗ｉｌ－２７抗体及びその使用
TW202310868A (zh) 2021-05-14 2023-03-16 美商克拉里斯生物醫療股份有限公司 用於治療眼睛疾病的生長因子組合物
JP2024534918A (ja) 2021-09-03 2024-09-26 ユニバーシティ オブ ベルン Ｑｔ延長症候群を治療するための組成物及び方法
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
KR102707065B1 (ko) 2022-03-08 2024-09-19 동국제약 주식회사 코아세르베이션법을 이용하여 현탁성이 개선된 미립구의 제조방법
CN119522094A (zh) 2022-04-19 2025-02-25 菲勒拉新西兰有限责任公司 脑铜病症的治疗
AU2023268600A1 (en) 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
KR20250012110A (ko) 2022-05-18 2025-01-23 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규 방법
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US20240025987A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
JPWO2023243689A1 (cg-RX-API-DMAC7.html) 2022-06-16 2023-12-21
AR130384A1 (es) 2022-09-02 2024-12-04 Univ Of Bern Composiciones y métodos para tratar el síndrome de qt largo
KR20250081950A (ko) 2022-09-02 2025-06-05 갈더마 홀딩 소시에떼 아노님 결절성 양진의 치료법
AU2023343470A1 (en) 2022-09-14 2025-02-06 Amgen Inc. Bispecific molecule stabilizing composition
WO2024076995A1 (en) 2022-10-03 2024-04-11 Insigna Inc. Compositions for non-surgical prevention of boar taint and aggressive behavior
AU2023365423A1 (en) 2022-10-18 2025-03-20 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell, and pharmaceutical
EP4613285A4 (en) 2022-11-04 2025-11-05 Talengen Int Ltd METHOD AND MEDICINE FOR PROMOTING THE ELIMINATION OF PATHOLOGICAL PROTEINS BY THE PROTEASOME-UBIQUITIN SYSTEM AND THE AUTOPHAGIC LYSOSOMAL SYSTEM
WO2024094217A1 (zh) 2022-11-04 2024-05-10 泰伦基国际有限公司 一种促进病理性tdp-43蛋白降解的方法和药物
WO2024121796A1 (en) 2022-12-07 2024-06-13 Fondazione Matilde Tettamanti E Menotti De Marchi Onlus Methods for generating genetically modified cytokine induced killer (cik) cells
CN115804830B (zh) * 2022-12-16 2024-08-20 浙江圣兆药物科技股份有限公司 一种缩短迟滞期的戈舍瑞林缓释植入剂
CA3274836A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Fused heterocyclic gamma-carbolines acting on the 5-HT2A serotonin receptor
EP4665344A1 (en) 2023-02-17 2025-12-24 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
CN120731226A (zh) 2023-02-21 2025-09-30 吉尼瑞姆股份公司 用于预防和治疗患有黏多糖贮积症ii型的受试者的溶酶体酶缺乏的药物组合物和方法
TW202444922A (zh) 2023-03-31 2024-11-16 國立大學法人大阪大學 用於預測敗血症患者之預後的生物標記及其用途
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025155602A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Method of treating hemophilia a
WO2025191291A1 (en) 2024-03-14 2025-09-18 Universidad Complutense De Madrid Methods for the prevention or treatment of erectile dysfunction (ed) by administering slpis (secretory leukocyte protease inhibitors)
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
JPS5324423B2 (cg-RX-API-DMAC7.html) * 1972-04-29 1978-07-20
JPS5017525A (cg-RX-API-DMAC7.html) * 1973-06-14 1975-02-24
JPS5749532B2 (cg-RX-API-DMAC7.html) * 1974-03-19 1982-10-22
JPS5035158A (cg-RX-API-DMAC7.html) * 1973-07-24 1975-04-03
JPS5726506B2 (cg-RX-API-DMAC7.html) * 1974-03-08 1982-06-04
JPS5314072B2 (cg-RX-API-DMAC7.html) * 1973-09-29 1978-05-15
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
CA1123984A (en) * 1977-11-16 1982-05-18 Yuzi Okuzumi Block copolymers of lactide and glycolide and surgical prosthesis therefrom
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
PH17900A (en) * 1979-09-12 1985-01-25 Lilly Co Eli Growth promotant controlled release formulations and method of treatment
US4333919A (en) * 1979-09-12 1982-06-08 Eli Lilly And Company Growth promotant controlled release formulations and method of treatment
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575066B2 (en) * 1983-08-26 1988-07-21 Novartis Ag Polyol ester

Also Published As

Publication number Publication date
JPH05221871A (ja) 1993-08-31
ES509647A0 (es) 1983-08-01
NO820433L (no) 1982-08-17
DK164845B (da) 1992-08-31
EP0058481B2 (en) 2003-05-21
GR76791B (cg-RX-API-DMAC7.html) 1984-09-04
YU31582A (en) 1985-04-30
PT74434B (en) 1983-07-14
ZA82565B (en) 1982-10-27
IE52535B1 (en) 1987-12-09
IE820165L (en) 1982-08-16
AU7998682A (en) 1982-08-26
US5004602A (en) 1991-04-02
NO162103B (no) 1989-07-31
AU2840789A (en) 1989-05-04
MY101545A (en) 1991-12-17
US4767628B1 (cg-RX-API-DMAC7.html) 1990-07-17
HK107890A (en) 1990-12-28
DK59182A (da) 1982-08-17
HU199695B (en) 1990-03-28
ATE22535T1 (de) 1986-10-15
JPS6264824A (ja) 1987-03-23
AU602623B2 (en) 1990-10-18
DE3273501D1 (en) 1986-11-06
YU44066B (en) 1990-02-28
AU582920B2 (en) 1989-04-13
PT74434A (en) 1982-03-01
JPS57150609A (en) 1982-09-17
NZ199732A (en) 1985-08-30
ES8307845A1 (es) 1983-08-01
JPH0774143B2 (ja) 1995-08-09
JPH031330B2 (cg-RX-API-DMAC7.html) 1991-01-10
EP0058481B1 (en) 1986-10-01
JPH05271051A (ja) 1993-10-19
HU186904B (en) 1985-10-28
CA1169090A (en) 1984-06-12
FI820467L (fi) 1982-08-17
AU6498886A (en) 1987-02-19
US4767628A (en) 1988-08-30
NO162103C (no) 1992-03-04
EP0058481A1 (en) 1982-08-25
JPH0686390B2 (ja) 1994-11-02
FI80594B (fi) 1990-03-30
JPH0157098B2 (cg-RX-API-DMAC7.html) 1989-12-04

Similar Documents

Publication Publication Date Title
US4767628B1 (cg-RX-API-DMAC7.html)
ES2009346A6 (es) Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
DE69000881D1 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
DE10075031I2 (de) Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
HUT45850A (en) Insecticides comprising azolinone derivatives as active ingredient and process for producing the active ingredients
IL90551A (en) Stable, injectable, aqueous pharmaceutical compositions for the treatment of cardiac conditions
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
HUT48217A (en) Pesticides comprising 5-methylamino-1-arylpyrazole derivatives as active ingredient and process for producing the active ingredients
ZA884622B (en) Pharmaceutical compositions in the form of pellets with enzymatically controlled release of the pharmaceutical,substance
HUT47233A (en) Process for producing pharmaceutical comprising phenol derivatives as active ingredient and for producing the active ingredients
HUT49596A (en) Herbicides comprising iminophenylthiazolidine derivatives as actie ingredient and process for producing the active ingredients
AU4434389A (en) Aqueous oral pharmaceutical preparation of diclofenac
HUT51105A (en) Pesticide comprising substituted acrylic acid ester derivatives as active ingredient and process for producing the active ingredients
HUT48096A (en) Insecticides comprising 2-imino-1,3-dithiethane derivatives as active ingredient and process for producing the active ingredients
FI880210L (fi) Menetelmä valmistaa peroraalista stabiloitua, tehoainetta hidastetusti ja kontrolloidusti vapauttavaa, lääkevalmistetta
HUT46323A (en) Compositions against pestiferous insects and process for producing compositions against zooparasites and comprising milbemycin derivatives as active ingredient and for producing the active ingredients
HUT47397A (en) Herbicides comprising sulfonyl-amino-guanidino-azine derivatives as active ingredient and process for producing the active ingredients
JPS6442470A (en) Guanidinecarboxylic acid esters, manufacture and medicinal composition
HUT49855A (en) Insecticides and nematocides comprising 5-ethylamino-1-arylpyrazole derivatives as active ingredient and process for producing the active ingredients
HUT47540A (en) Herbicides comprising 1-phenyl-5-exomethylene-pyrrolidin-2-one derivatives as active ingredient and process for producing the active ingredients
NL7810163A (nl) Arylalkylalkaancarbonzuren, geneesmiddel met als werk- zaam bestanddeel alkaancarbonzuur en werkwijze voor de bereiding van de arylalkylalkaancarbonzuren.
HUT47240A (en) Insecticides and acaricides comprising benzoyl-urea derivatives as active ingredient and process for producing the active ingredients
IT8821430A0 (it) Esteri dell'acido tiamorfolinone carbossilico e di suoi derivati, loro procedimento di preparazione e loro impiego nel settore cosmetico e nel settore dermo farmaceutico.
DK45592A (da) Poly(lactid-co-glycolid)polymer omfattende mindst 25 mol% maelkesyreenheder og op til 75 mol% glycosyreenheder samt fremgangsmaade til fremstilling heraf
HUT46643A (en) Process for producing styryl ketones and pharmaceutical compositions comprising the same as active ingredient

Legal Events

Date Code Title Description
NDB Extension of term for standard patent granted (sect.76)

Free format text: 14/10/2006

PC Assignment registered

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER WAS: ZENECA LIMITED